Introduction to aristocort (triamcinolone)
Aristocort is a brand name for the corticosteroid medication triamcinolone. This powerful anti-inflammatory and immunosuppressive drug belongs to the glucocorticoid class of steroids and is used to treat a wide variety of medical conditions. Triamcinolone works by mimicking the effects of cortisol, a hormone naturally produced by the adrenal glands that helps regulate metabolism, immune response, and stress reactions. Since its introduction into medical practice, Aristocort has become a foundation treatment for conditions ranging from allergic reactions and skin disorders to rheumatic diseases and respiratory conditions. Patients seeking affordable healthcare solutions often turn to a Happy Family Store for reliable access to this medication.
Triamcinolone is available in multiple formulations, including oral tablets, topical creams and ointments, injectable suspensions, dental pastes, and nasal sprays. Each formulation is designed to target specific conditions and deliver the medication effectively to the affected area while minimizing systemic side effects. The versatility of Aristocort makes it a valuable tool in the modern medical arsenal, though it requires careful handling and professional supervision due to its potent effects on the body’s endocrine system.
The mechanism of action of triamcinolone involves binding to glucocorticoid receptors within cells, which then translocate to the nucleus and modulate gene expression. This process leads to increased production of anti-inflammatory proteins such as lipocortin and decreased production of pro-inflammatory mediators including prostaglandins, leukotrienes, and cytokines. By dampening the inflammatory cascade at multiple points, Aristocort can effectively reduce swelling, redness, heat, and pain associated with inflammation. This broad-spectrum anti-inflammatory activity is what makes triamcinolone useful across such a diverse range of medical conditions.
Medical uses and indications
Aristocort is prescribed for numerous conditions across different medical specialties. In dermatology, triamcinolone acetonide cream and ointment are used to treat eczema, psoriasis, contact dermatitis, seborrheic dermatitis, and other inflammatory skin conditions. The topical formulation provides localized relief with minimal systemic absorption when used as directed. For more severe or widespread skin conditions, systemic oral triamcinolone may be necessary to achieve adequate disease control.
In rheumatology, Aristocort injections are commonly administered directly into inflamed joints to relieve pain and swelling associated with osteoarthritis, rheumatoid arthritis, bursitis, tendinitis, and gout. Intra-articular injections deliver a high concentration of the medication precisely where it is needed, often providing rapid and sustained relief that can last for weeks or months. This approach minimizes systemic exposure and reduces the risk of side effects compared to long-term oral steroid therapy.
Respiratory conditions such as severe asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis may also be treated with triamcinolone. While inhaled corticosteroids are more commonly used for chronic asthma management, systemic Aristocort may be prescribed during acute exacerbations or for patients with severe disease that does not respond adequately to other treatments. The anti-inflammatory effects help reduce airway swelling and mucus production, improving breathing and lung function.
Allergic conditions including severe allergic reactions, angioedema, drug hypersensitivity reactions, and anaphylaxis may be treated with triamcinolone, often in combination with antihistamines and epinephrine. The medication helps suppress the overactive immune response that characterizes these conditions, preventing further tissue damage and promoting recovery. Chronic allergic conditions such as urticaria (hives) and atopic dermatitis may also benefit from short-term Aristocort therapy during flare-ups.
Gastrointestinal conditions like ulcerative colitis and Crohn’s disease may be treated with oral triamcinolone during active inflammatory episodes. The medication helps reduce intestinal inflammation, decrease diarrhea, and promote healing of the intestinal lining. However, due to the potential for significant side effects with long-term use, Aristocort is typically reserved for acute management rather than maintenance therapy in inflammatory bowel disease.
Ophthalmic conditions including uveitis, iritis, and certain types of conjunctivitis may be treated with triamcinolone eye drops or injections. The anti-inflammatory effects help preserve vision by reducing swelling and preventing scar formation in delicate eye tissues. Close monitoring by an ophthalmologist is essential when using corticosteroids in the eye due to the risk of increased intraocular pressure and cataract formation.
Certain blood disorders such as immune thrombocytopenic purpura (ITP) and hemolytic anemia may respond to Aristocort therapy, as the medication can suppress the immune system’s destruction of blood cells. Similarly, some types of cancer, particularly lymphomas and leukemias, may be treated with triamcinolone as part of combination chemotherapy regimens. The medication helps reduce tumor-associated inflammation and can directly induce apoptosis (programmed cell death) in certain malignant cells.
Organ transplant recipients may receive Aristocort as part of their immunosuppressive regimen to prevent rejection of the transplanted organ. By suppressing the immune system’s natural tendency to attack foreign tissue, triamcinolone helps maintain graft function and prolong transplant survival. This application requires careful dosing and monitoring due to the increased risk of infection associated with immunosuppression.
Dosage forms and strengths
Aristocort is available in several different dosage forms, each with specific strengths and indications. Oral triamcinolone tablets are typically available in 4 mg, 8 mg, and 16 mg strengths, with dosing adjusted based on the condition being treated, the patient’s age and weight, and their response to therapy. The usual starting dose for adults ranges from 4 mg to 48 mg per day, depending on disease severity, with gradual tapering as symptoms improve.
Topical triamcinolone acetonide preparations include creams, ointments, and lotions in concentrations of 0.025%, 0.1%, and 0.5%. Lower concentrations are suitable for maintenance therapy and treatment of mild conditions, while higher concentrations are reserved for more severe or resistant lesions. The choice between cream and ointment bases depends on the nature of the skin condition and the area being treated, with ointments generally providing more potent occlusion and better penetration.
Injectable triamcinolone acetonide and triamcinolone hexacetonide suspensions are available for intra-articular, intralesional, and intramuscular administration. Typical doses for joint injections range from 5 mg to 40 mg depending on the size of the joint being treated, with larger joints such as the knee requiring higher doses than smaller joints such as the interphalangeal joints of the fingers.
Triamcinolone dental paste (Kenalog in Orabase) contains 0.1% triamcinolone acetonide and is used for the treatment of inflammatory and ulcerative conditions of the oral cavity, including aphthous ulcers (canker sores), lichen planus, and erosive lesions. The paste adheres to moist oral tissues, providing sustained release of the medication directly to the affected area.
Triamcinolone acetonide nasal spray is used for the treatment of allergic rhinitis and nasal polyps, with typical dosing of two sprays in each nostril once daily. This formulation delivers the medication directly to the nasal mucosa, minimizing systemic absorption and reducing the risk of side effects associated with oral corticosteroids.
Mechanism of action
The therapeutic effects of Aristocort (triamcinolone) are mediated through its interaction with the glucocorticoid receptor, a type of nuclear receptor that functions as a transcription factor. When triamcinolone enters a target cell, it binds to the glucocorticoid receptor in the cytoplasm, causing a conformational change that releases the receptor from its associated heat shock proteins. This activated receptor-ligand complex then translocates into the cell nucleus, where it binds to specific DNA sequences called glucocorticoid response elements (GREs) in the promoter regions of target genes.
Binding to GREs can either enhance or suppress gene transcription, leading to increased production of anti-inflammatory proteins such as lipocortin-1, interleukin-10, and I-kappa-B-alpha, while decreasing production of pro-inflammatory proteins including various cytokines (interleukin-1, interleukin-2, interleukin-6, tumor necrosis factor-alpha), chemokines, and adhesion molecules. Also, triamcinolone can inhibit the activity of phospholipase A2, reducing the release of arachidonic acid from membrane phospholipids and thereby decreasing the production of prostaglandins, leukotrienes, and other eicosanoids that mediate inflammation.
Triamcinolone also suppresses the immune system by inhibiting the proliferation and function of various immune cells, including T lymphocytes, B lymphocytes, macrophages, and eosinophils. It reduces the production of antibodies by B cells and impairs the ability of antigen-presenting cells to activate T cells. These immunosuppressive effects are beneficial in autoimmune conditions and allergic reactions and contribute to the increased risk of infection associated with corticosteroid therapy.
The mineralocorticoid activity of triamcinolone is relatively weak compared to its glucocorticoid activity, which means it has less effect on sodium and water retention than some other corticosteroids. This makes Aristocort a preferred choice when a potent anti-inflammatory effect is needed without significant fluid retention. However, at high doses or with prolonged use, some mineralocorticoid effects may still occur.
Side effects and adverse reactions
While Aristocort is highly effective for many conditions, it is associated with many potential side effects, particularly when used at high doses or for extended periods. The side effect profile of triamcinolone is similar to that of other systemic corticosteroids and can affect virtually every organ system in the body. Patients should be educated about these potential adverse effects and monitored regularly by their healthcare provider.
Metabolic and endocrine side effects are among the most common concerns with triamcinolone therapy. The medication can cause increased appetite, weight gain, and redistribution of body fat leading to the characteristic cushingoid appearance with moon face, buffalo hump, and central obesity. Glucose metabolism is often affected, with many patients developing hyperglycemia or worsening of pre-existing diabetes mellitus. Regular monitoring of blood glucose levels is recommended, and diabetic patients may require adjustment of their antidiabetic medications during treatment.
Musculoskeletal side effects include osteoporosis, osteopenia, and an increased risk of fractures, particularly with long-term use. Triamcinolone inhibits bone formation and increases bone resorption, leading to decreased bone mineral density. Avascular necrosis of the femoral head is a particularly serious but less common complication that can cause severe hip pain and disability. Myopathy with proximal muscle weakness may also occur, especially with high doses or prolonged therapy.
Gastrointestinal effects include an increased risk of peptic ulcer disease, gastritis, and pancreatitis. Triamcinolone can mask the symptoms of gastrointestinal perforation, making the diagnosis of this life-threatening complication more difficult. Patients with a history of peptic ulcer disease should use this medication with caution and may benefit from concurrent gastroprotective therapy.
Cardiovascular effects include hypertension, fluid retention, and an increased risk of thromboembolic events. Triamcinolone can cause sodium and water retention, leading to edema and worsening of congestive heart failure in susceptible patients. Hyperlipidemia and accelerated atherosclerosis have also been associated with long-term corticosteroid use.
Neuropsychiatric side effects are common and can range from mild mood changes to severe psychiatric disturbances. Euphoria, insomnia, irritability, and anxiety are frequently reported, while depression, psychosis, and suicidal ideation occur less commonly but require immediate medical attention. Patients with a personal or family history of psychiatric illness may be at increased risk for these effects.
Dermatological effects include skin thinning, easy bruising, striae (stretch marks), acne, impaired wound healing, and increased susceptibility to skin infections. Topical triamcinolone can cause localized skin atrophy, telangiectasia (spider veins), and perioral dermatitis, particularly with prolonged use on the face or in skin folds.
Ocular effects include an increased risk of posterior subcapsular cataracts and elevated intraocular pressure (glaucoma), particularly with systemic use or with prolonged topical ophthalmic administration. Regular eye examinations are recommended for patients on long-term triamcinolone therapy.
Immunological effects include suppression of the immune system and increased susceptibility to bacterial, viral, fungal, and parasitic infections. Triamcinolone can reactivate latent infections such as tuberculosis, hepatitis B, and herpes zoster (shingles). Patients should avoid exposure to chickenpox or measles while on systemic corticosteroid therapy, as these infections can be particularly severe in immunocompromised individuals.
Drug interactions
Aristocort can interact with numerous other medications, potentially altering their efficacy or increasing the risk of adverse effects. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and aspirin taken concurrently with triamcinolone increase the risk of gastrointestinal ulceration and bleeding. Patients requiring both medications should be monitored closely and may benefit from gastroprotective agents such as proton pump inhibitors.
Anticoagulants and antiplatelet medications, including warfarin, heparin, and clopidogrel, may have altered effects when combined with triamcinolone. Corticosteroids can either potentiate or inhibit the effects of anticoagulants, necessitating more frequent monitoring of coagulation parameters such as the international normalized ratio (INR) in patients receiving warfarin.
Antidiabetic medications, including insulin and oral hypoglycemic agents, may require dose adjustment when triamcinolone therapy is initiated or discontinued due to the medication’s effects on glucose metabolism. Blood glucose levels should be monitored closely, particularly in the early stages of concurrent therapy.
Certain medications that induce liver enzymes, particularly CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital, can increase the clearance of triamcinolone and reduce its effectiveness. Conversely, CYP3A4 inhibitors such as ketoconazole, itraconazole, and certain protease inhibitors can decrease triamcinolone clearance and increase the risk of toxicity.
Estrogen-containing medications, including oral contraceptives and hormone replacement therapy, can increase the concentration of corticosteroid-binding globulin and alter the distribution and metabolism of triamcinolone, potentially requiring dose adjustments. Patients starting or stopping estrogen therapy while on Aristocort should be monitored for changes in clinical response.
Vaccines, particularly live attenuated vaccines such as the measles-mumps-rubella (MMR) vaccine, varicella vaccine, and intranasal influenza vaccine, should generally be avoided during systemic corticosteroid therapy due to the risk of vaccine-induced infection. Inactivated vaccines may be less effective due to immunosuppression and should ideally be administered before or after the course of corticosteroid therapy.
Contraindications and precautions
Aristocort is contraindicated in patients with known hypersensitivity to triamcinolone or any component of the formulation. Systemic fungal infections are an absolute contraindication to systemic corticosteroid use unless the infection is being treated with appropriate antifungal therapy. Live or live attenuated vaccines should not be administered to patients receiving immunosuppressive doses of corticosteroids.
Special caution is required when using triamcinolone in patients with congestive heart failure, hypertension, or renal impairment due to the medication’s potential for fluid retention and electrolyte imbalances. Patients with pre-existing psychiatric conditions should be monitored closely for exacerbation of symptoms, and those with a history of steroid-induced psychosis should use this medication only when absolutely necessary.
Patients with diabetes mellitus require close monitoring of blood glucose levels, as triamcinolone can impair glucose tolerance. Those with osteoporosis or significant risk factors for bone loss should receive appropriate preventive therapy, including calcium and vitamin D supplementation, and possibly bisphosphonate therapy for long-term treatment courses.
Patients with a history of tuberculosis, positive tuberculin skin test results, or recent exposure to tuberculosis require careful evaluation before initiating corticosteroid therapy, as the immunosuppressive effects of triamcinolone can reactivate latent infections. Prophylactic antituberculosis therapy may be indicated in certain patients.
Patients with a history of peptic ulcer disease, diverticulitis, recent intestinal anastomoses, or nonspecific ulcerative colitis should use triamcinolone with caution due to the increased risk of gastrointestinal complications. The medication can also mask the signs and symptoms of peritonitis and other gastrointestinal emergencies.
Special populations
Pregnancy category C: Triamcinolone has been shown to cause teratogenic effects in animal studies, including cleft palate and growth retardation. However, adequate and well-controlled studies in pregnant women are lacking. Aristocort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should be advised about the potential risks and use effective contraception during treatment.
Triamcinolone is excreted in breast milk and may suppress growth and interfere with endogenous corticosteroid production in nursing infants. The decision to breastfeed while taking Aristocort should be made in consultation with a healthcare provider, weighing the benefits of breastfeeding against the potential risks to the infant. Lower doses and shorter treatment duration are preferred when breastfeeding.
Geriatric patients may be more susceptible to the adverse effects of corticosteroids, particularly osteoporosis, fluid retention, and psychiatric disturbances. Lower starting doses and careful monitoring are recommended for elderly patients, along with appropriate preventive measures such as calcium and vitamin D supplementation to protect bone health.
Pediatric patients require careful dosing based on body weight or surface area, and long-term treatment should be avoided when possible due to the risk of growth suppression. Growth and development should be monitored regularly in children receiving prolonged corticosteroid therapy. The smallest effective dose should be used for the shortest possible duration.
Withdrawal and tapering
Abrupt discontinuation of Aristocort after prolonged use can lead to acute adrenal insufficiency, a potentially life-threatening condition characterized by hypotension, hypoglycemia, electrolyte disturbances, and shock. This occurs because exogenous corticosteroids suppress the hypothalamic-pituitary-adrenal (HPA) axis, reducing the adrenal glands’ natural production of cortisol. When the medication is suddenly stopped, the adrenal glands may be unable to mount an adequate stress response.
To prevent adrenal insufficiency, triamcinolone should be tapered gradually rather than discontinued abruptly. The tapering schedule depends on the dose and duration of treatment, with longer courses and higher doses requiring more gradual reduction. A typical tapering schedule might reduce the daily dose by 2.5 mg every 3 to 7 days, though individualization is essential based on patient response and the underlying condition being treated.
During periods of stress such as surgery, trauma, or severe illness, patients who have recently discontinued corticosteroids or are currently on therapy may require stress dose coverage with additional corticosteroids. Medical alert identification should be carried by patients on prolonged corticosteroid therapy to ensure appropriate management in emergency situations.
Clinical efficacy and research evidence
The clinical efficacy of triamcinolone has been shown across numerous controlled clinical trials spanning several decades. In dermatological conditions such as psoriasis and atopic dermatitis, topical triamcinolone acetonide has shown consistent superiority over placebo and comparable efficacy to other potent corticosteroids in reducing plaque thickness, scaling, erythema, and pruritus. Meta-analyses of clinical trials have established a clear dose-response relationship, with higher potency formulations providing more rapid and complete clearance of lesions, albeit with a corresponding increase in the risk of local adverse effects.
In rheumatological applications, intra-articular triamcinolone injections have demonstrated significant efficacy in reducing pain and improving function in patients with osteoarthritis of the knee, hip, and shoulder. A landmark randomized controlled trial published in the New England Journal of Medicine evaluated triamcinolone acetonide injections for knee osteoarthritis and found that they provided significant pain relief for up to 6 months compared to placebo, though the study also raised questions about potential accelerated cartilage loss with repeated injections that require further investigation. The current evidence suggests that intra-articular corticosteroids are most appropriate for patients with moderate to severe pain who have not responded adequately to conservative measures.
For allergic conditions, triamcinolone has shown efficacy in reducing both nasal and ocular symptoms of seasonal and perennial allergic rhinitis. Intranasal triamcinolone acetonide spray has been shown to improve nasal congestion, rhinorrhea, sneezing, and nasal itching within the first week of treatment, with sustained benefit throughout the allergy season. Comparative studies have suggested that intranasal corticosteroids, including triamcinolone, are more effective than oral antihistamines for controlling nasal congestion, which is often the most bothersome symptom for patients with allergic rhinitis.
In respiratory medicine, systemic triamcinolone has been evaluated for the treatment of acute asthma exacerbations and severe COPD exacerbations. Studies have demonstrated that early administration of oral or intravenous corticosteroids reduces the need for hospitalization, shortens recovery time, and improves lung function in patients with acute asthma. For COPD, short courses of systemic corticosteroids reduce treatment failure rates and accelerate recovery, though the optimal dose and duration of therapy remain subjects of ongoing research.
Comparative analysis with other corticosteroids
Triamcinolone has a specific position within the corticosteroid potency hierarchy. It is approximately 5 times more potent than hydrocortisone, 1.25 times more potent than prednisone, and approximately 0.2 to 0.3 times as potent as dexamethasone. This intermediate potency makes triamcinolone suitable for many indications where moderate to potent anti-inflammatory activity is required without the full potency of the most potent corticosteroids, which carry correspondingly higher risks of adverse effects.
Compared to prednisone, triamcinolone has slightly different tissue distribution and receptor binding characteristics that may influence its clinical effects. Some clinicians and patients report that triamcinolone produces less appetite stimulation and weight gain than prednisone, though individual responses vary considerably. The choice between different corticosteroids is often based on factors such as the specific condition being treated, the desired balance of anti-inflammatory and mineralocorticoid effects, the route of administration, and individual patient characteristics and preferences.
For topical use, triamcinolone acetonide is classified as a medium-potency to high-potency corticosteroid depending on the concentration and formulation. It has an important middle ground between lower-potency agents such as hydrocortisone and higher-potency agents such as clobetasol propionate. This positioning makes it suitable for maintenance therapy after initial disease control has been achieved with higher-potency agents, and for treating conditions that require more than low-potency corticosteroids but do not warrant the risks associated with super-high-potency preparations.
Formulation considerations and pharmaceutical technology
The pharmaceutical formulation of triamcinolone influences its clinical efficacy and safety profile. Topical triamcinolone acetonide is available in cream, ointment, and lotion bases, each with distinct characteristics that affect drug release, skin penetration, and patient acceptability. Ointment bases provide greater occlusion and enhance drug penetration through the stratum corneum, making them more potent than cream formulations of the same concentration. Creams are more cosmetically acceptable for use on visible areas such as the face and hands but provide less potent drug delivery. Lotions are useful for treating large or hairy areas where even application is important.
The vehicle composition of topical corticosteroids also influences their stability, release kinetics, and skin penetration. Modern formulations often incorporate penetration enhancers, humectants, and emollients that improve drug delivery while maintaining skin hydration and barrier function. The choice of vehicle is an important clinical consideration, and prescribers should select the formulation that best matches the characteristics of the lesion and the treatment goals.
Injectable formulations of triamcinolone are available as crystalline suspensions that form a depot at the injection site, providing sustained release of the medication over weeks to months. The particle size and crystal structure of the suspension affect the duration of action and the potential for adverse effects such as post-injection flare or crystal-induced synovitis. Triamcinolone hexacetonide has a longer duration of action than triamcinolone acetonide due to its lower aqueous solubility, making it preferred for large joint injections where prolonged benefit is desired.
Long-term management strategies
For patients requiring long-term corticosteroid therapy, several strategies can help minimize adverse effects while maintaining therapeutic efficacy. The principle of using the lowest effective dose for the shortest possible duration applies to all corticosteroid therapy. For chronic conditions, steroid-sparing agents such as methotrexate, azathioprine, mycophenolate, or biologic therapies should be considered to reduce or eliminate corticosteroid requirements. These disease-modifying antirheumatic drugs (DMARDs) and biologic agents can provide disease control with different safety profiles.
Calcium and vitamin D supplementation are recommended for all patients expected to receive corticosteroid therapy for more than three months, as these interventions can partially mitigate corticosteroid-induced bone loss. Bisphosphonate therapy should be considered for patients at high risk of fracture, including postmenopausal women, men over 50 years of age, and patients with prior fragility fractures or reduced bone mineral density. Monitoring with dual-energy X-ray absorptiometry (DEXA) scans at baseline and periodically during therapy is recommended to assess bone health.
Immunizations should be updated before initiating corticosteroid therapy whenever possible. The pneumococcal vaccine and annual influenza vaccine are recommended for all patients on chronic corticosteroid therapy. Live vaccines are contraindicated during immunosuppressive therapy and should be administered at least four weeks before starting treatment or delayed until the immune system has recovered after discontinuation. Patients should be counseled about infection prevention measures and the importance of seeking prompt medical attention for any signs of infection.
Emerging research and future directions
Research into triamcinolone continues to evolve, with ongoing studies exploring new indications, novel formulations, and improved delivery systems. The development of targeted drug delivery systems, including nanoparticles and microparticles, aims to enhance drug delivery to specific tissues while minimizing systemic exposure and side effects. These technologies have the potential to improve the therapeutic index of triamcinolone for both topical and systemic applications.
Combination therapies incorporating triamcinolone with other active agents are being investigated for various conditions. In dermatology, combination formulations of triamcinolone with antifungal agents, antibiotics, or keratolytic agents may improve treatment outcomes for complex conditions such as fungal infections with inflammatory components. In rheumatology, the combination of intra-articular triamcinolone with viscosupplements such as hyaluronic acid is being studied for osteoarthritis, with some evidence suggesting improved outcomes compared to either treatment alone.
The role of triamcinolone in emerging therapeutic areas such as the treatment of keloids and hypertrophic scars continues to expand. Intralesional triamcinolone injection remains the first-line treatment for keloids, and research continues to optimize dosing regimens and combination therapies to improve outcomes and reduce recurrence rates. The use of triamcinolone in the treatment of plantar fasciitis, trigger finger, and other musculoskeletal conditions continues to evolve as clinical experience accumulates and new evidence emerges.
Patient education and monitoring
Patients prescribed Aristocort should receive comprehensive education about their medication, including the importance of adhering to the prescribed dosing schedule, not abruptly discontinuing therapy, and reporting any unusual symptoms to their healthcare provider promptly. They should understand that corticosteroids are not the same as anabolic steroids used by athletes for performance enhancement and should not be shared with others.
Regular monitoring during triamcinolone therapy should include periodic assessment of blood pressure, blood glucose levels, serum electrolytes, bone mineral density, and ophthalmic examinations. Patients should maintain a healthy lifestyle with adequate calcium and vitamin D intake, weight-bearing exercise, and avoidance of tobacco and excessive alcohol consumption to minimize the risk of osteoporosis.
Patients should be advised to avoid exposure to infections, practice good hand hygiene, and receive appropriate vaccinations before starting corticosteroid therapy when possible. They should report any signs of infection, including fever, cough, or unusual symptoms, promptly to their healthcare provider, as infections can progress rapidly in immunocompromised patients.